Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bari – page 30

401 clinical trials in Bari, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bari at a glance
401
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

401 trials in Bari

Open in trial search

Acute myeloid leukaemia (in remission)

Not recruiting

Study on the Effectiveness of Decitabine and Venetoclax for Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Anaemia+1

Not recruiting

Study of SEL120 Monohydrochloride for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
  • Sponsor:Gcp-Service International West GmbH

Chronic myeloid leukaemia

Not recruiting

Comparison of nilotinib versus imatinib treatment in newly diagnosed chronic myeloid leukemia patients to achieve treatment-free remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

HER2 positive breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer

Not recruiting

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Warm autoimmune haemolytic anaemia

Not recruiting

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Not recruiting

Study on Long-Term Safety of GSK1070806 for Patients with Moderate to Severe Atopic Dermatitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IgG1 kappa monoclonal antibody against interleukin 18
  • Sponsor:Glaxosmithkline Research & Development Limited

Age-related macular degeneration

Not recruiting

Study on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on Long-term Safety and Efficacy of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy Using a Drug Combination

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Argenx

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bari

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and malignant pleural mesothelioma. Research evaluates new therapeutic approaches and drug combinations.

  • Colorectal Cancer Treatment Studies
  • Lung Cancer Therapies
  • Mesothelioma Management

Advanced clinical trials testing targeted therapies and immunotherapy approaches.

02 Infectious Disease Prevention

Investigations into vaccines and preventive treatments for various infectious conditions, particularly respiratory syncytial virus (RSV) and influenza. Studies include both pediatric and adult populations.

  • Vaccine Development
  • RSV Prevention
  • Influenza Protection

Focus on immunogenicity and safety in different age groups.

03 Hematologic Disorders

Research examining treatments for blood-related conditions, including chronic myeloid leukemia and acute myeloid leukemia. Studies evaluate novel therapeutic approaches and drug combinations.

  • Leukemia Treatments
  • Targeted Therapies
  • Clinical Outcomes

Emphasis on personalized treatment approaches and molecular targeting.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.